No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Brief pembrolizumab monotherapy followed by doxorubicin, vinblastine, and dacarbazine was both effective and safe in untreated early unfavourable and advanced stage classical Hodgkin lymphoma

byKathleen Lau

March 25, 2021

in StudyGraphics

#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025

Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025

Brain lesions on MRI linked with subsequent increased stroke risk

Neurology

Moderate to severe TBI is associated with elevated malignant brain tumor risk

September 1, 2025

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

Non-obstructive lesions with high lipid content may increase risk for future adverse cardiac outcomes

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Mechanics of SARS-CoV-2 spread in a sleep-away camp

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Poor sleep efficiency associated with major adverse cardiovascular events

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports